Cabot Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cabot Corporation on December 2, 2015. The filing addresses a significant change in executive leadership structure due to the temporary medical leave of the Chief Executive Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
- CEO Departure: Patrick M. Prevost, President and Chief Executive Officer, commenced a temporary medical leave of absence on December 2, 2015, with an expected return in January 2016.
- Interim Leadership: The Board of Directors established an "Interim Office of the Chief Executive Officer" (CEO Office) to assume Mr. Prevost's responsibilities.
- CEO Office Composition: The interim office consists of four executives who will retain their current titles:
- Eduardo E. Cordeiro (Executive Vice President and CFO)
- Brian A. Berube (Senior Vice President and General Counsel)
- Sean D. Keohane (Executive Vice President and President, Reinforcement Materials Segment)
- Nicholas S. Cross (Executive Vice President and President, Performance Chemicals and Specialty Fluids Segments)
- Oversight: The CEO Office reports to the Board of Directors, with oversight provided by John F. O'Brien, the non-Executive Chairman.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or new risk factors. Management commentary is limited to the operational transition plan. The filing notes that there are no changes to the compensation arrangements of the interim officers resulting from their new roles. It discloses specific tax withholding transactions for these officers in November 2015 totaling $171,655, $120,170, $88,852, and $88,357, respectively.
Investor Verification Checklist
- Confirm the expected return date of CEO Patrick M. Prevost (stated as January 2016).
- Review the attached Press Release (Exhibit 99.1) for additional details on the transition.
- Verify that no changes to executive compensation were made as a result of the interim appointment.
- Monitor subsequent filings for updates on Mr. Prevost's health status or any extension of the interim leadership structure.